USA flag logo/image

An Official Website of the United States Government

Company Information:

Name: MOLECULAR TARGETING TECHNOLOGIES, INC.
Address: 833 LINCOLN AVE, UNIT 9
WEST CHESTER, PA
Located in HUBZone: No
Woman-Owned: No
Minority-Owned: No
URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $2,197,211.00 10
SBIR Phase II $1,046,000.00 2
STTR Phase I $1,899,498.00 3
STTR Phase II $3,345,476.00 2

Award List:

Diagnosis of Myocardial Infarction with Tc-99m Glucarate

Award Year / Program / Phase: 1995 / SBIR / Phase I
Agency: HHS
Principal Investigator: Koon Pak
Award Amount: $98,500.00
Abstract:
We will develop a noninvasive hyperacute diagnostic reagent for acute myocardial infarct detectionvisualization. It should be a low-tech, technetium-99m based reagent which can be used with simple gare already available in almost all hospitals in the US. It should be sensitive and be able to… More

IMAGING OF DVT AND PE WITH TC-99M-BITISTATIN

Award Year / Program / Phase: 1998 / SBIR / Phase I
Agency: HHS
Principal Investigator: Pak, Koon Y
Award Amount: $100,000.00

POTENT RABIES VACCINES FOR FREE RANGING CARNIVORES

Award Year / Program / Phase: 2000 / SBIR / Phase I
Agency: HHS
Principal Investigator: Koon Y. Pak
Award Amount: $100,000.00

Potent Rabies Vaccines for Free Ranging Carnivores

Award Year / Program / Phase: 2002 / SBIR / Phase II
Agency: HHS
Principal Investigator: Koon Y. Pak
Award Amount: $700,000.00

Selection and Testing of Recombinant CAV 2- Rabies Vaccine for Oral Immunization of Wildlife

Award Year / Program / Phase: 2006 / SBIR / Phase I
Agency: USDA
Principal Investigator: Jeffrey A. Mattis, Sr. Vice President, Scientific Affairs
Award Amount: $79,700.00
Abstract:
Extensive worldwide reservoirs of rabies virus (RV) in wildlife and stray dogs continue to pose a serious risk of lethal infection of humans and cause a high economic burden. Immunization of wildlife and stray dogs with live vaccines is the only effective method to control and eventually eliminate… More

A novel rhabdovirus-based anthrax vaccine

Award Year / Program / Phase: 2006 / STTR / Phase I
Agency: HHS
Research Institution: THOMAS JEFFERSON UNIVERSITY
Principal Investigator: Matthias J. Schnell
Award Amount: $1,067,665.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): Bioterrorism using anthrax is a major risk in the US and abroad, and, therefore, has been classified as an NIAID Category A Priority Pathogen. The best strategy against anthrax is a safe and effective vaccine. The existing human vaccine against Anthrax has a… More

Selection and Testing of Recombinant CAV 2- Rabies Vaccine for Oral Immunization of Wildlife

Award Year / Program / Phase: 2007 / SBIR / Phase II
Agency: USDA
Principal Investigator: Jeffrey A. Mattis, Sr. Vice President, Scientific Affairs
Award Amount: $346,000.00
Abstract:
Oral immunization of wildlife and stray dogs with live vaccines is the only effective method to control rabies in carnivore species worldwide. Because adenoviruses replicate on mucosal surfaces, they represent excellent vectors that can be administered both orally and intranasally. The nearly ideal… More

Radiohybridization Imaging of HER2 Oncogene to Detect Breast Cancer

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator: Koon Y. Pak
Award Amount: $808,065.00
Abstract:
DESCRIPTION (provided by applicant): Aggressive, invasive breast cancer will attack gt180,000 women in the US in 2007, and will take the lives of gt40,000 women. Mammograms detect lumps in breasts, H80% of which are benign, and H20% are malignant. Lumps ar e biopsied to determine whether they are… More

A novel vaccine: botulinum neurotoxin subunit on a viral carrier.

Award Year / Program / Phase: 2008 / STTR / Phase I
Agency: HHS
Research Institution: N/A
Principal Investigator:
Award Amount: $669,400.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): According to the NIAID fact sheet on Botulism, the extreme toxicity of botulinum neurotoxins (BoNT) and the ease of production, transport, and delivery make this an agent of extreme bioterrorism concern. Nonetheless, a lthough there are major vaccine development… More

Superior Near-IR Dyes for Bioimaging

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: Arunkumar Easwaran
Award Amount: $176,838.00
Abstract:
DESCRIPTION (provided by applicant): Optical imaging is an advanced technique to image biotechnology products like gels, sensors, and micro arrays. It is also used increasingly to monitor specific molecular pathways in animals. This latter technique uses f luorescent dyes that absorb and emit… More

Bright and Stable Near-IR dyes for Bioimaging

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: Arunkumar Easwaran
Award Amount: $193,511.00
Abstract:
DESCRIPTION (provided by applicant): Optical imaging is an advanced technique to image biotechnology products like gels, sensors, and micro arrays. It is also used increasingly to monitor specific molecular pathways in animals. This latter technique uses f luorescent dyes that absorb and emit… More

Dual Modality Labels for Macro and Micro Detection and Quantification of Stem Cel

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Brian D. Gray
Award Amount: $196,224.00
Abstract:
DESCRIPTION (provided by applicant): Stem cells hold promise for treatment of a number of disease states such as Parkinson's, Alzheimer's, spinal cord injury, diabetes, ischemia stroke and heart disease since stem cells have the potential under certain phy siological conditions to develop into many… More

Human Rabies Virus Vaccine Development

Award Year / Program / Phase: 2011 / STTR / Phase II
Agency: HHS
Research Institution: THOMAS JEFFERSON UNIVERSITY
Principal Investigator: James P. Mcgettigan – 215-503-4629
Award Amount: $836,316.00
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): Current human rabies virus (RV) vaccines are effective if administered in an appropriate and timely manner and therefore, RV infection is a vaccine-preventable disease. However, immunization protocols are complex, requiring multiple doses over a period of weeks… More

A novel vaccine: botulinum neurotoxin subunit on a viral carrier.

Award Year / Program / Phase: 2012 / STTR / Phase II
Agency: HHS
Research Institution: THOMAS JEFFERSON UNIVERSITY
Principal Investigator: Matthias J. Schnell – 215-503-4634
Award Amount: $2,509,160.00
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): According to the NIAID fact sheet on Botulism, the extreme toxicity of botulinum neurotoxins (BoNT) and the ease of production, transport, and delivery make this an agent of extreme bioterrorism concern. Nonetheless, although there are major vaccine… More

Anionic Phospholipid-Selective PET/SPECT Agent for Infection Imaging

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Brian D. Gray – 610-738-7938
Award Amount: $224,438.00
Abstract:
DESCRIPTION (provided by applicant): Although a rapid and accurate diagnosis is crucial to the management of patients suspected of bacterial infection, the currently available radiopharmaceuticals are not capable of distinguishing between sterile inflammation and bacterial infections. Our goal is to… More

Biased Agonism In GPCR Drug Discovery: Application To Somatostatin Agonists

Award Year / Program / Phase: 2013 / SBIR / Phase I
Agency: HHS
Principal Investigator: Brian D. Gray – 610-738-7938
Award Amount: $219,935.00
Abstract:
DESCRIPTION: Tracing neuronal connections with lipophilic carbocyanine dyes has revolutionized neuroanatomical tract tracing and is an essential feature to understand development of brain connections in both control and mutant mice in particular since multiple colors of dyes can be used. More… More